News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Video
04 February 2026

Dealmakers: Brigitte Bruengger, SERV

TXF spoke with Brigitte Bruengger, head of large enterprises, SME & acquisition at SERV, to outline the recent challenges for Swiss exporters, its scheme for attracting more...

Interview
06 February 2026

Perspectives: Kexim ups emphasis on equity and project fund...

Seung-Hoon Lee is now head of Export-Import Bank of Korea (Kexim’s) investment finance team, having recently been director of the new development finance team in the agency’s...